Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Zepbound outperformed Wegovy on both the primary endpoint and all five secondary endpoints. Notably, 31.6% of Zepbound users achieved 25% weight loss, with only 16.1% of those using Wegovy ...

U.S. approvals for Zepbound and Wegovy were based on separate trials in which Lilly's drug helped patients lose more than 22% of their weight after 72 weeks, while Wegovy led to 15% weight loss ...

Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are prescription drugs used for weight loss and weight management. Both drugs come as a liquid solution for injection under the skin.

Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial Dec. 04, 2024 8:57 AM ET Eli Lilly and Company (LLY) Stock, NVO Stock By: Preeti Singh, SA News Editor 9 Comments ...